Ensituximab
Ensituximab
Ensituximab (pronunciation: en-si-tux-i-mab) is a monoclonal antibody designed for the treatment of certain types of cancer. It is a type of immunotherapy that targets the MUC5AC antigen, which is overexpressed in many cancers.
Etymology
The name "Ensituximab" follows the World Health Organization's guidelines for the nomenclature of monoclonal antibodies. The suffix "-mab" indicates that it is a monoclonal antibody, while the infix "-tuxi-" suggests its target, in this case, the MUC5AC antigen.
Mechanism of Action
Ensituximab works by binding to the MUC5AC antigen on the surface of cancer cells. This binding triggers an immune response that leads to the destruction of the cancer cells. This mechanism of action is similar to other monoclonal antibodies used in cancer treatment, such as cetuximab and panitumumab.
Clinical Trials
Ensituximab has been studied in several clinical trials for its effectiveness in treating various types of cancer, including colorectal cancer and pancreatic cancer. Results from these trials have shown promise, but further research is needed to fully understand the potential benefits and risks of this treatment.
Side Effects
Like all medications, ensituximab can cause side effects. Common side effects include fatigue, nausea, and diarrhea. More serious side effects can include allergic reactions and infusion-related reactions. Patients should discuss these potential side effects with their healthcare provider before starting treatment with ensituximab.
See Also
External links
- Medical encyclopedia article on Ensituximab
- Wikipedia's article - Ensituximab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski